273 related articles for article (PubMed ID: 25616122)
1. Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.
Younossi Z; Henry L
Aliment Pharmacol Ther; 2015 Mar; 41(6):497-520. PubMed ID: 25616122
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
Fagundes RN; Ferreira LEVVC; Pace FHL
PLoS One; 2020; 15(8):e0237005. PubMed ID: 32813740
[TBL] [Abstract][Full Text] [Related]
3. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
Younossi ZM; Stepanova M; Henry L; Nader F; Younossi Y; Hunt S
Medicine (Baltimore); 2016 Jul; 95(28):e4151. PubMed ID: 27428205
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
5. The impact of hepatitis C virus outside the liver: Evidence from Asia.
Younossi ZM; Tanaka A; Eguchi Y; Lim YS; Yu ML; Kawada N; Dan YY; Brooks-Rooney C; Negro F; Mondelli MU
Liver Int; 2017 Feb; 37(2):159-172. PubMed ID: 27748564
[TBL] [Abstract][Full Text] [Related]
6. Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity.
Younossi ZM; Stepanova M; Esteban R; Jacobson I; Zeuzem S; Sulkowski M; Henry L; Nader F; Cable R; Afendy M; Hunt S
Medicine (Baltimore); 2017 Feb; 96(7):e5914. PubMed ID: 28207507
[TBL] [Abstract][Full Text] [Related]
7. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
Younossi ZM; Stepanova M; Nader F; Lam B; Hunt S
Aliment Pharmacol Ther; 2015 Aug; 42(3):286-95. PubMed ID: 26059536
[TBL] [Abstract][Full Text] [Related]
8. An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
Younossi ZM; Stepanova M; Henry L; Nader F; Hunt S
Am J Gastroenterol; 2016 Jun; 111(6):808-16. PubMed ID: 27021197
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186
[TBL] [Abstract][Full Text] [Related]
10. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.
Younossi Z; Henry L
Dig Liver Dis; 2014 Dec; 46 Suppl 5():S186-96. PubMed ID: 25458773
[TBL] [Abstract][Full Text] [Related]
11. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.
Cacoub P; Bourliere M; Asselah T; De Ledinghen V; Mathurin P; Hézode C; Henry L; Stepanova M; Younossi ZM
Value Health; 2018 Oct; 21(10):1218-1225. PubMed ID: 30314623
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
[TBL] [Abstract][Full Text] [Related]
13. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
[TBL] [Abstract][Full Text] [Related]
14. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
Younossi ZM; Stepanova M; Nader F; Henry L
J Am Geriatr Soc; 2016 Feb; 64(2):386-93. PubMed ID: 26825683
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
[TBL] [Abstract][Full Text] [Related]
16. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Nader F; Hunt S
J Hepatol; 2014 Apr; 60(4):741-7. PubMed ID: 24333184
[TBL] [Abstract][Full Text] [Related]
17. The impact of antiviral therapy for hepatitis C on the quality of life: a perspective.
Dusheiko G
Liver Int; 2017 Jan; 37 Suppl 1():7-12. PubMed ID: 28052638
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt.
Youssef NF; El Kassas M; Farag A; Shepherd A
BMC Gastroenterol; 2017 Jan; 17(1):18. PubMed ID: 28109264
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Puoti M; Orkin C; Hunt SL
J Infect Dis; 2015 Aug; 212(3):367-77. PubMed ID: 25583164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
